JP2010523476A - ミトコンドリアアルデヒドデヒドロゲナーゼ−２モジュレーター及びその使用方法 - Google Patents

ミトコンドリアアルデヒドデヒドロゲナーゼ−２モジュレーター及びその使用方法 Download PDF

Info

Publication number
JP2010523476A
JP2010523476A JP2009552756A JP2009552756A JP2010523476A JP 2010523476 A JP2010523476 A JP 2010523476A JP 2009552756 A JP2009552756 A JP 2009552756A JP 2009552756 A JP2009552756 A JP 2009552756A JP 2010523476 A JP2010523476 A JP 2010523476A
Authority
JP
Japan
Prior art keywords
aldh2
group
substituted
subject
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009552756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523476A5 (enExample
Inventor
モチリーローゼン，ダリア
チェン，チェホン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2010523476A publication Critical patent/JP2010523476A/ja
Publication of JP2010523476A5 publication Critical patent/JP2010523476A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2009552756A 2007-03-08 2008-03-07 ミトコンドリアアルデヒドデヒドロゲナーゼ−２モジュレーター及びその使用方法 Pending JP2010523476A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90596307P 2007-03-08 2007-03-08
PCT/US2008/003092 WO2008112164A2 (en) 2007-03-08 2008-03-07 Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014194188A Division JP2015061836A (ja) 2007-03-08 2014-09-24 ミトコンドリアアルデヒドデヒドロゲナーゼ−２モジュレーター及びその使用方法

Publications (2)

Publication Number Publication Date
JP2010523476A true JP2010523476A (ja) 2010-07-15
JP2010523476A5 JP2010523476A5 (enExample) 2014-11-20

Family

ID=39760277

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009552756A Pending JP2010523476A (ja) 2007-03-08 2008-03-07 ミトコンドリアアルデヒドデヒドロゲナーゼ−２モジュレーター及びその使用方法
JP2014194188A Pending JP2015061836A (ja) 2007-03-08 2014-09-24 ミトコンドリアアルデヒドデヒドロゲナーゼ−２モジュレーター及びその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014194188A Pending JP2015061836A (ja) 2007-03-08 2014-09-24 ミトコンドリアアルデヒドデヒドロゲナーゼ−２モジュレーター及びその使用方法

Country Status (8)

Country Link
US (3) US20110105602A2 (enExample)
EP (1) EP2126574B1 (enExample)
JP (2) JP2010523476A (enExample)
KR (1) KR20090117950A (enExample)
CN (1) CN101669030B (enExample)
AU (1) AU2008226947B2 (enExample)
CA (1) CA2679882C (enExample)
WO (1) WO2008112164A2 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015078145A (ja) * 2013-10-16 2015-04-23 国立大学法人広島大学 アルデヒドデヒドロゲナーゼの活性を増強するための医薬組成物
JP2016514154A (ja) * 2013-03-14 2016-05-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
WO2019098288A1 (ja) * 2017-11-15 2019-05-23 学校法人 慶應義塾 抗腫瘍剤及び配合剤
WO2019151241A1 (ja) * 2018-01-31 2019-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ａｌｄｈ２活性化剤
JP2019525762A (ja) * 2016-07-28 2019-09-12 アドバンスト バイオデザイン Ａｌｄｈアイソザイムの特異的基質

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105602A2 (en) 2007-03-08 2011-05-05 Daria Mochly-Rosen Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
ES2477552T3 (es) 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
JP2012506856A (ja) 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法
US20140088187A1 (en) * 2010-12-14 2014-03-27 Beth Israel Deaconess Medical Center Androgen receptor inhibitors and methods of use thereof
US10457659B2 (en) 2011-04-29 2019-10-29 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for increasing proliferation of adult salivary stem cells
TWI567061B (zh) 2011-07-01 2017-01-21 吉李德科學股份有限公司 用於治療成癮之化合物
WO2014031982A2 (en) * 2012-08-24 2014-02-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating pain
CN103191103A (zh) * 2013-04-15 2013-07-10 中南大学 乙醛脱氢酶激活物alda-1的合成方法及其用途
CN103923077B (zh) * 2013-07-05 2016-03-02 高尔医药科技(上海)有限公司 两种乙醛脱氢酶激动剂、其制备方法及用途
WO2015084731A1 (en) * 2013-12-02 2015-06-11 The Board Of Trustees Of The Leland Stanford Junior University Aldehyde dehydrogenase inhibitors and methods of use thereof
HUE051255T2 (hu) * 2014-02-19 2021-03-01 Aviv Therapeutics Inc Mitokondriális aldehid dehidrogenáz 2 (ALDH2) kötõ policiklusos amidok és alkalmazásuk rák kezelésére
CN108864034A (zh) * 2018-06-04 2018-11-23 中国人民解放军第二军医大学 酰胺类醛脱氢酶激动剂、其合成方法及用途
CN111909138A (zh) * 2019-05-09 2020-11-10 上海仕谱生物科技有限公司 抑制tdg活性的化合物
US20220226286A1 (en) * 2019-05-23 2022-07-21 Ekyj Consulting Ii, Llc Compositions and methods for the treatment and mitigation of alcohol-induced skin flushing
CA3194020A1 (en) 2020-11-02 2022-05-05 Alchemedicine, Inc. Compound, aldehyde dehydrogenase 2 activating agent, pharmaceutical composition, and therapeutic and/or prophylactic drug
AU2023257780A1 (en) 2022-04-22 2024-07-04 Alchemedicine, Inc. Compound, aldehyde dehydrogenase 2 activator, pharmaceutical composition, and therapeutic and/or prophylactic drug

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02115168A (ja) * 1988-08-31 1990-04-27 Pfizer Inc 抗うつ薬ｎ―置換ニコチンアミド化合物
JPH06321903A (ja) * 1992-07-23 1994-11-22 Ishihara Sangyo Kaisha Ltd アミド系化合物又はその塩、それらの製造方法及びそれらを含有する有害動物防除剤
WO2001032928A2 (en) * 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
JP2001508811A (ja) * 1998-04-20 2001-07-03 藤沢薬品工業株式会社 ｃＧＭＰ−ホスホジエステラーゼ阻害剤としてのアントラニル酸誘導体
JP2002511386A (ja) * 1997-12-22 2002-04-16 イーライ・リリー・アンド・カンパニー アミド形成反応のための触媒およびその方法
WO2003030937A1 (en) * 2001-10-05 2003-04-17 Ono Pharmaceutical Co., Ltd. Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
EP1402887A1 (en) * 2002-09-18 2004-03-31 Jerini AG New compounds for the inhibition of undesired cell proliferation and use thereof
US20050215548A1 (en) * 2002-07-05 2005-09-29 Cyclacel Limited Bisarylsulfonamide compounds and their use in cancer therapy
WO2005110422A2 (en) * 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
JP2010501578A (ja) * 2006-08-25 2010-01-21 ビテ ファーマシューティカルズ， インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型のインヒビター
JP2010520206A (ja) * 2007-03-02 2010-06-10 メルク・シャープ・エンド・ドーム・コーポレイション ビピリジンカルボキサミドオレキシン受容体アンタゴニスト

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2319808A (en) 1939-08-31 1943-05-25 Squibb & Sons Inc Sterol derivatives and process for producing same
JPH01203351A (ja) 1988-02-05 1989-08-16 Mitsui Petrochem Ind Ltd １，４−ジヒドロキシナフタレン誘導体および医薬
JPH023351A (ja) 1988-06-16 1990-01-08 Oki Electric Ind Co Ltd 印刷装置
JPH03184973A (ja) 1989-12-14 1991-08-12 Rooman Kogyo:Kk 放射線障害防護剤
US5260323A (en) 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
DE4201047A1 (de) * 1992-01-17 1993-07-22 Bayer Ag Substituierte isoxazolcarbonsaeureamide
US5272137A (en) * 1992-02-14 1993-12-21 Mcneil-Pfc, Inc. Aqueous pharmaceutical suspension for pharmaceutical actives
JP3833281B2 (ja) 1995-02-03 2006-10-11 日本曹達株式会社 ２，６−ジクロロイソニコチン酸ベンジルアミド誘導体及び植物病害防除剤
EP1019385B1 (en) 1995-09-15 2004-01-14 PHARMACIA & UPJOHN COMPANY Aminoaryl oxazolidinone n-oxides
US6072050A (en) 1996-06-11 2000-06-06 Pioneer Hi-Bred International, Inc. Synthetic promoters
FR2751645B1 (fr) 1996-07-29 1998-12-24 Sanofi Sa Amines pour la fabrication de medicaments destines a empecher la proliferation de cellules tumorales
HUP0100699A3 (en) 1997-10-31 2002-11-28 Aventis Pharma Ltd West Mallin Substituted anilides and pharmaceuticals comprising them
AR019190A1 (es) 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
US6780883B2 (en) 1998-11-05 2004-08-24 Warner-Lambert Company Amide inhibitors of microsomal triglyceride transfer protein
EP1133487B1 (en) 1998-11-25 2004-09-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Antioxidants
GB9919558D0 (en) 1999-08-18 1999-10-20 Hoechst Schering Agrevo Gmbh Fungicidal compounds
WO2001079489A2 (en) 2000-04-18 2001-10-25 Millennium Pharmaceuticals, Inc. 39228, a human alcohol dehydrogenase and uses therefor
AU2001288432A1 (en) 2000-09-01 2002-03-22 Icos Corporation Materials and methods to potentiate cancer treatment
AU9355101A (en) 2000-09-15 2002-03-26 Anormed Inc Chemokine receptor binding heterocyclic compounds
US7141590B2 (en) 2000-12-29 2006-11-28 Ucb Sa Pharmaceutical uses and synthesis of nicotinanilide-N-oxides
DOP2002000332A (es) 2001-02-14 2002-08-30 Warner Lambert Co Inhibidores de piridina de metaloproteinasas de la matriz
US6678516B2 (en) 2001-05-21 2004-01-13 Nokia Corporation Method, system, and apparatus for providing services in a privacy enabled mobile and Ubicom environment
US7547716B2 (en) 2001-06-08 2009-06-16 Institute Of Medicinal Molecular Design, Inc. Sulfonamide derivatives
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
US20030100034A1 (en) 2001-10-16 2003-05-29 Millennium Pharmaceuticals, Inc. 9136, a human aldehyde dehydrogenase family member and uses therefor
KR20040077884A (ko) 2002-01-31 2004-09-07 화이자 프로덕츠 인코포레이티드 （3-｛〔（4-3급-뷰틸-벤질）-（피리딘-3-설폰일）-아미노〕-메틸｝-페녹시）-아세트산의 대사산물
GB2403474B (en) 2002-04-18 2006-10-11 Inst Med Molecular Design Inc Amide derivatives
US7294642B2 (en) 2002-09-06 2007-11-13 Elan Pharmaceuticals, Inc. 1,3-Diamino-2-hydroxypropane pro-drug derivatives
EP1402888A1 (en) * 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7022850B2 (en) 2003-05-22 2006-04-04 Bristol-Myers Squibb Co. Bicyclicpyrimidones and their use to treat diseases
JP4359754B2 (ja) 2003-07-03 2009-11-04 三菱瓦斯化学株式会社 基板の洗浄剤
WO2005007889A1 (en) 2003-07-21 2005-01-27 Oncotherapy Science, Inc. Method for diagnosing colorectal cancers
WO2005011561A2 (en) 2003-08-04 2005-02-10 Labcoat, Ltd. Stent coating apparatus and method
GB0318814D0 (en) 2003-08-11 2003-09-10 Smithkline Beecham Corp Novel compounds
FR2861071B1 (fr) 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[phenyl(alkylpiperidin-2-yl) methyl]benzamide, leur prepartation et leur application en therapeutique
FR2861074B1 (fr) 2003-10-17 2006-04-07 Sanofi Synthelabo Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
AU2004298048A1 (en) 2003-12-09 2005-06-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for modulating mitochondrial aldehyde dehydrogenase-2
US20080021083A1 (en) * 2004-03-03 2008-01-24 Daley Thomas E 4-Methylpyrazole Formulations for Inhibiting Ethanol Intolerance
CN1749415A (zh) * 2004-09-15 2006-03-22 上海人类基因组研究中心 硝酸甘油治疗急性心绞痛疗效检测方法和试剂盒
WO2006053120A1 (en) 2004-11-12 2006-05-18 Bristol-Myers Squibb Company IMIDAZO-FUSED THIAZOLO[4,5-b]PYRIDINE BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME
US7888374B2 (en) 2005-01-28 2011-02-15 Abbott Laboratories Inhibitors of c-jun N-terminal kinases
DOP2006000051A (es) 2005-02-24 2006-08-31 Lilly Co Eli Inhibidores de vegf-r2 y métodos
HRP20100272T2 (hr) 2005-09-23 2010-07-31 Pfizer Products Incorporated Piridinaminosulfonil supstituirani benzamidi kao inhibitori citokroma p450 3a4 (cyp3a4)
JP2009524589A (ja) 2005-12-22 2009-07-02 ワイス 置換されたイソキノリン−１，３（２ｈ，４ｈ）−ジオン、１−チオキソ−１，４−ジヒドロ−２ｈ−イソキノリン−３−オン誘導体、および１，４−ジヒドロ−３（２ｈ）−イソキノロン、ならびにキナーゼインヒビターとしてのそれらの使用
WO2007110237A2 (en) 2006-03-28 2007-10-04 Novartis Ag Amide derivatives and their application for the treatment of g protein related diseases
JP5528699B2 (ja) 2006-05-16 2014-06-25 武田薬品工業株式会社 縮合複素環化合物およびその用途
US20080003585A1 (en) 2006-06-29 2008-01-03 Bio-Rad Laboratories, Inc., A Corporation Of The State Of Delaware Purification and amplification of nucleic acids in a microfluidic device
US20080032995A1 (en) 2006-07-27 2008-02-07 Jeff Zablocki Aldh-2 inhibitors in the treatment of drug addiction
PE20080906A1 (es) 2006-08-17 2008-07-05 Kemia Inc Derivados heteroarilo como inhibidores de citocina
ATE507205T1 (de) 2006-12-11 2011-05-15 Genetics Co Inc Aromatische 1,4-di-carboxylamide und deren verwendung
CN101611007A (zh) 2006-12-20 2009-12-23 先灵公司 新颖的jnk抑制剂
WO2008103354A2 (en) 2007-02-20 2008-08-28 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
US20110105602A2 (en) 2007-03-08 2011-05-05 Daria Mochly-Rosen Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester PROCESS FOR EXTENDING THE LIFE OF EUKARYOTIC ORGANISMS
RU2010153656A (ru) 2008-06-04 2012-07-20 Амбрилиа Байофарма Инк. (Ca) Ингибиторы интегразы вич из пиридоксина
US9187426B2 (en) 2008-06-27 2015-11-17 Novartis Ag Organic compounds
ES2477552T3 (es) * 2008-09-08 2014-07-17 The Board Of Trustees Of The Leland Stanford Junior University Moduladores de la actividad de la aldehidodeshidrogenasa y métodos de uso de los mismos
JP2012506856A (ja) * 2008-10-28 2012-03-22 ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ アルデヒドデヒドロゲナーゼのモジュレーターおよびその使用方法

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02115168A (ja) * 1988-08-31 1990-04-27 Pfizer Inc 抗うつ薬ｎ―置換ニコチンアミド化合物
JPH06321903A (ja) * 1992-07-23 1994-11-22 Ishihara Sangyo Kaisha Ltd アミド系化合物又はその塩、それらの製造方法及びそれらを含有する有害動物防除剤
JP2002511386A (ja) * 1997-12-22 2002-04-16 イーライ・リリー・アンド・カンパニー アミド形成反応のための触媒およびその方法
JP2001508811A (ja) * 1998-04-20 2001-07-03 藤沢薬品工業株式会社 ｃＧＭＰ−ホスホジエステラーゼ阻害剤としてのアントラニル酸誘導体
WO2001032928A2 (en) * 1999-11-05 2001-05-10 Phase-1 Molecular Toxicology Methods of determining individual hypersensitivity to an agent
WO2003030937A1 (en) * 2001-10-05 2003-04-17 Ono Pharmaceutical Co., Ltd. Remedies for stress diseases comprising mitochondrial benzodiazepine receptor antagonists
US20050215548A1 (en) * 2002-07-05 2005-09-29 Cyclacel Limited Bisarylsulfonamide compounds and their use in cancer therapy
EP1402887A1 (en) * 2002-09-18 2004-03-31 Jerini AG New compounds for the inhibition of undesired cell proliferation and use thereof
WO2005110422A2 (en) * 2004-05-19 2005-11-24 Boehringer Ingelheim International Gmbh Treatment of diseases associated with altered level of amyloid beta peptides
JP2010501578A (ja) * 2006-08-25 2010-01-21 ビテ ファーマシューティカルズ， インコーポレイテッド １１β−ヒドロキシステロイドデヒドロゲナーゼ１型のインヒビター
JP2010520206A (ja) * 2007-03-02 2010-06-10 メルク・シャープ・エンド・ドーム・コーポレイション ビピリジンカルボキサミドオレキシン受容体アンタゴニスト

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
JPN6013021831; ＲＥＧＩＳＴＲＹ（ＳＴＮ）［ｏｎｌｉｎｅ］ *
JPN6013021836; Ｊ．　Ｃｏｍｂ．　Ｃｈｅｍ． ８, 2006, ８９０-８９６ *
JPN6013021838; Ｂｉｏｃｈｉｍｉｃａ　ｅｔ　Ｂｉｏｐｈｙｓｉｃａ　Ａｃｔａ １２７３, 1996, ２１-３０ *
JPN6013021841; ＲＥＧＩＳＴＲＹ（ＳＴＮ）［ｏｎｌｉｎｅ］ *
JPN6013021842; ＲＥＧＩＳＴＲＹ（ＳＴＮ）［ｏｎｌｉｎｅ］ *
JPN6013021845; ＲＥＧＩＳＴＲＹ（ＳＴＮ）［ｏｎｌｉｎｅ］ *
JPN6013021846; ＲＥＧＩＳＴＲＹ（ＳＴＮ）［ｏｎｌｉｎｅ］ *
JPN6013021848; ＲＥＧＩＳＴＲＹ（ＳＴＮ）［ｏｎｌｉｎｅ］ *
JPN6013021849; ＲＥＧＩＳＴＲＹ（ＳＴＮ）［ｏｎｌｉｎｅ］ *
JPN6013021851; ＲＥＧＩＳＴＲＹ（ＳＴＮ）［ｏｎｌｉｎｅ］ *
JPN6013021853; ＲＥＧＩＳＴＲＹ（ＳＴＮ）［ｏｎｌｉｎｅ］ *
JPN6013021855; ＲＥＧＩＳＴＲＹ（ＳＴＮ）［ｏｎｌｉｎｅ］ *
JPN6013021856; ＲＥＧＩＳＴＲＹ（ＳＴＮ）［ｏｎｌｉｎｅ］ *
JPN6013021859; Ｏｒｇ．　Ｌｅｔｔ． ９，２, 2007, １８３-６ *
JPN7013001688; ＩＬ　Ｆａｒｍａｃｏ-Ｅｄ．Ｓｃ． ３２，１１, 1977, ８１３-８２６ *
JPN7013001689; Ｋｈｉｍｉｋｏ-Ｆａｒｍａｔｓｅｖｔｉｃｈｅｓｋｉｉ　Ｚｈｕｒｎａｌ ２８，１, 1994, ７-１０ *
JPN7013001691; Ｅｕｒ．　Ｊ．　Ｏｒｇ．　Ｃｈｅｍ． , 2001, ７０７-７１２ *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514154A (ja) * 2013-03-14 2016-05-19 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー ミトコンドリアアルデヒドデヒドロゲナーゼ−２調節因子およびその使用方法
JP2015078145A (ja) * 2013-10-16 2015-04-23 国立大学法人広島大学 アルデヒドデヒドロゲナーゼの活性を増強するための医薬組成物
JP2019525762A (ja) * 2016-07-28 2019-09-12 アドバンスト バイオデザイン Ａｌｄｈアイソザイムの特異的基質
JP7050748B2 (ja) 2016-07-28 2022-04-08 アドヴァンスト・バイオデザイン Ａｌｄｈアイソザイムの特異的基質
US11519014B2 (en) 2016-07-28 2022-12-06 Advanced Biodesign Specific substrate of an ALDH isoenzyme
WO2019098288A1 (ja) * 2017-11-15 2019-05-23 学校法人 慶應義塾 抗腫瘍剤及び配合剤
WO2019151241A1 (ja) * 2018-01-31 2019-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 Ａｌｄｈ２活性化剤
US10406126B2 (en) 2018-01-31 2019-09-10 Eisai R&D Management Co., Ltd. ALDH2 activator

Also Published As

Publication number Publication date
US9102651B2 (en) 2015-08-11
US20120010248A1 (en) 2012-01-12
CA2679882A1 (en) 2008-09-18
US20090082431A1 (en) 2009-03-26
WO2008112164A2 (en) 2008-09-18
EP2126574A2 (en) 2009-12-02
AU2008226947B2 (en) 2014-07-17
US20110105602A2 (en) 2011-05-05
CA2679882C (en) 2015-12-29
CN101669030B (zh) 2016-01-13
US9315484B2 (en) 2016-04-19
JP2015061836A (ja) 2015-04-02
WO2008112164A3 (en) 2008-11-13
AU2008226947A1 (en) 2008-09-18
KR20090117950A (ko) 2009-11-16
CN101669030A (zh) 2010-03-10
EP2126574A4 (en) 2012-02-22
EP2126574B1 (en) 2015-12-23
US20150105456A1 (en) 2015-04-16

Similar Documents

Publication Publication Date Title
JP2010523476A (ja) ミトコンドリアアルデヒドデヒドロゲナーゼ−２モジュレーター及びその使用方法
US8772295B2 (en) Modulators of aldehyde dehydrogenase and methods of use thereof
EP2337563B1 (en) Modulators of aldehyde dehydrogenase activity and methods of use thereof
US9670162B2 (en) Mitochondrial aldehyde dehyrogenase-2 modulators and methods of use thereof
AU2014250605A1 (en) Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof
WO2015084731A1 (en) Aldehyde dehydrogenase inhibitors and methods of use thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110304

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130502

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130808

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140523

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20140924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20140925

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20141201

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150116